Full-Time

Director Scientific Communications

CNS

Updated on 8/1/2026

 Otsuka Pharmaceutical

Otsuka Pharmaceutical

1,001-5,000 employees

Global pharmaceutical company developing medicines

Compensation Overview

$186.5k - $278.9k/yr

+ Incentive opportunity

Remote in USA

Remote

Category
Medical, Clinical & Veterinary (1)
Required Skills
Data Analysis

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Requirements
  • An advanced degree is required: Doctor of Pharmacy, Doctor of Medicine, Doctor of Philosophy, or an equivalent degree in science, medicine, or a related field.
  • At least 10 years of experience in Medical Affairs, Scientific Communications, or related roles within the pharmaceutical or biotechnology industry is required.
  • At least 3 to 5 years of prior leadership experience, including developing and managing team members, is required.
  • Demonstrated experience leading global communication strategies and integrated planning processes is required.
  • Strong experience leading cross-functional teams and influencing senior stakeholders is required.
  • The candidate must be able to translate complex scientific data into clear, strategic communication plans.
  • The candidate must have strong leadership and facilitation skills, including the ability to chair cross-functional teams.
  • The candidate must have expertise in content strategy, omnichannel engagement, and digital communication tools.
  • The candidate must have strong project management capabilities and experience managing multiple high-priority initiatives simultaneously.
  • The candidate must have executive presence and the ability to communicate effectively with stakeholders.
  • The candidate must have a strategic mindset, strong business acumen, and the ability to align scientific communications with enterprise goals.
  • The candidate must have experience leveraging innovation, including artificial intelligence and digital tools, to enhance content development and delivery.
Responsibilities
  • Lead the development and execution of a comprehensive, globally aligned medical communications strategy across assigned central nervous system assets.
  • Provide input to long-term communication priorities aligned with asset strategy, lifecycle stage, and the evolving external landscape.
  • Translate scientific and clinical insights into integrated communication approaches that support stakeholder engagement and decision-making.
  • Act as a strategic partner to senior cross-functional leaders to ensure alignment with enterprise and asset-level priorities.
  • Lead cross-functional scientific teams for assigned asset and therapeutic-area deliverables.
  • Lead the execution of Medical Communication Plans, including content strategy and deliverables, communication channels and external engagement planning, and congress execution.
  • Ensure Integrated Medical Communications Plans are integrated into annual asset planning processes and aligned with broader medical and business strategies.
  • Drive accountability for timely, high-quality execution of all Integrated Medical Communications Plan deliverables.
  • Support development and refinement of the Scientific Communication Platform, scientific narrative, and core lexicon across Medical Affairs communications.
  • Ensure consistency, clarity, and scientific rigor across all content and communication channels globally.
  • Provide strategic oversight for disease-state education materials, core field medical materials, data dissemination assets, congress-related materials, and external engagement tools.
  • Ensure content strategies are modular, scalable, and optimized for omnichannel delivery.
  • Drive the design and execution of innovative content and communication channel strategies, including digital and omnichannel engagement approaches.
  • Collaborate with internal teams to develop new tools and platforms for scientific communication, including digital, social, and interactive formats.
  • Champion emerging technologies such as artificial-intelligence-enabled content development, personalization, and automation to improve efficiency and impact.
  • Ensure content is designed for end users to enhance accessibility, engagement, and scientific understanding.
  • Serve as a core leader within cross-functional asset teams.
  • Translate emerging clinical data into actionable communication strategies.
  • Ensure alignment and appropriate scientific integration across global and regional initiatives while maintaining Medical Affairs independence.
  • Ensure communications are scientifically accurate, evidence-based, and compliant with internal policies and external regulations.
  • Establish and oversee governance frameworks for content development, review, and lifecycle management.
  • Act as an escalation point for complex scientific or compliance-related content decisions.
  • Maintain high standards of quality, consistency, and ethical communication practices.
  • Lead annual scope-of-work planning and resource allocation for scientific communications deliverables.
  • Oversee agency partnerships, including selection, contracting, performance management, and optimization.
  • Drive operational excellence, process improvements, and scalable content development models.
  • Ensure efficient delivery of high-quality outputs within budget and timelines.
  • Lead, develop, and mentor a high-performing team of Associate Directors, Managers, and cross-functional contributors.
  • Foster a culture of scientific excellence, innovation, accountability, and collaboration.
  • Build organizational capability in scientific communications, including best-practice sharing and process standardization.
  • Promote a learner-first, inclusive mindset in content development and team culture.
  • Stay current with advancements in scientific communications, digital engagement, and the external healthcare landscape.
  • Gather and implement best practices across regions to drive consistency and innovation.
  • Use insights, analytics, and stakeholder feedback to continuously optimize communication strategies and execution.
Desired Qualifications
  • Experience in the central nervous system therapeutic area.
 Otsuka Pharmaceutical

Otsuka Pharmaceutical

View

Otsuka Pharmaceutical is a global health-focused company that develops and markets medicines and nutraceutical products. It creates pharmaceuticals like Abilify (aripiprazole), an antipsychotic, and consumer health brands such as Pocari Sweat, an ion-replacement drink. Its products work by medical mechanisms (Abilify modulates dopamine and serotonin receptors to treat psychiatric conditions) and by supporting hydration and electrolyte balance (Pocari Sweat). Otsuka differentiates itself through a long, international growth path from its roots as a Japanese chemical manufacturer, a balanced portfolio spanning prescription drugs and health beverages, and a philosophy of developing new products to improve health worldwide. Its goal is to deliver healthier outcomes for people around the world by expanding access to innovative medicines and health-related consumer products.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval opens a large U.S. ADHD market for Simtriyo.
  • Phase 3 trials showed symptom improvement as early as week one.
  • Otsuka’s pharmaceutical revenue base supports launch investment and specialty commercialization.

What critics are saying

  • DEA scheduling can delay Simtriyo’s U.S. launch and revenue conversion.
  • Boxed warnings create pediatric prescribing friction and post-marketing scrutiny.
  • Entrenched ADHD competitors and payer barriers threaten uptake despite approval.

What makes Otsuka Pharmaceutical unique

  • Founded in 1921, Otsuka built from chemical raw materials to global healthcare.
  • Otsuka combines pharmaceuticals and nutraceuticals under one health-focused corporate strategy.
  • Centanafadine gives Otsuka a novel, once-daily ADHD mechanism beyond traditional stimulants.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
SonoThera, Inc.
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.

The Associated Press
Mar 25th, 2026
Otsuka's Voyxact shows 82.5% hematuria improvement in IgA nephropathy trial at 48 weeks

Otsuka presented new Phase 3 VISIONARY trial data for VOYXACT (sibeprenlimab-szsi) in IgA nephropathy patients at the 2026 ISN World Congress of Nephrology. The analyses showed 82.5% of patients receiving sibeprenlimab achieved negative microscopic hematuria at week 48, compared with 52.6% on placebo. Median time to achieve hematuria negativity was nine weeks versus 24 weeks for placebo. VOYXACT, approved under accelerated approval in the US, is a monoclonal antibody that inhibits APRIL, a key driver in IgAN pathogenesis. Previously reported data showed the drug met its primary endpoint with a 51.2% placebo-adjusted reduction in proteinuria at nine months. The trial continues evaluating sibeprenlimab's effect on preserving kidney function over 24 months.

Business Wire
Mar 2nd, 2026
Paradise ultrasound renal denervation system now covered by insurance in Japan for resistant hypertension

Otsuka Medical Devices and Otsuka Pharmaceutical have launched the Paradise Ultrasound Renal Denervation system in Japan, with National Health Insurance coverage effective 1 March. The device, developed by US subsidiary Recor Medical, treats resistant hypertension by reducing sympathetic nerve overactivity surrounding renal arteries. The system targets patients whose blood pressure remains above target despite using three different antihypertensive medications, including a diuretic. This marks Japan's first ultrasound renal denervation treatment. The Paradise system received FDA approval in the US in November 2023. Under a co-promotion agreement, both Otsuka companies will leverage their cardiovascular and renal expertise to deliver the treatment according to guidelines established by Japanese medical societies. The system offers a new option for resistant hypertension patients at high risk of serious cardiovascular complications.